Objective:
To explore the clinical efficacy and safety of Qigong in reducing the self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores of patients with chronic obstructive pulmonary disease (COPD).
Methods:
We searched CNKI, Wan fang, Chongqing VIP, China Biology Medicine disc, PubMed, Cochrane Library, and EMBASE for studies published as of Dec 31, 2018. All randomized controlled trials of Qigong in COPD patients, which met the inclusion criteria were included. The Cochrane bias risk assessment tool was used for literature evaluation. RevMan 5.3 software was used for meta-analysis.
Results:
Six studies (combined n = 415 patients) met the inclusion criteria. Compared with conventional therapy alone, Qigong in combination with conventional therapy significantly improved the following outcome measures: SDS score [mean difference (MD) −3.99, 95% CI (−6.17, −1.82),
P
< .001,
I
2
= 69%]; SAS score[MD −4.57, 95% CI (−5.67, −3.48),
P
<
.001,
I
2
= 15%]; forced expiratory volume in one second/prediction (FEV
1
% pred) [MD 3.77, 95% CI (0.97,6.58),
P
< .01,
I
2
= 0]; forced expiratory volume in one second (FEV
1
) [MD 0.21, 95% CI (0.13, 0.30),
P
<
.001,
I
2
= 0%]; forced vital capacity (FVC) [MD 0.28, 95% CI (0.16, 0.40),
P
<
.001,
I
2
= 0]; 6-minute walk test (6MWT) distance [MD 39.31, 95% CI (18.27, 60.34),
P
<
.001,
I
2
= 32%]; and St. George's Respiratory Questionnaire (SGRQ) total score [MD −11.42, 95% CI (−21.80, −1.03),
P
<
.05,
I
2
= 72%].
Conclusion:
Qigong can improve the SDS and SAS scores of COPD patients, and has auxiliary effects on improving lung function, 6MWT distance, and SGRQ score.
